文献速递血脂与心血管预防冠心病

老年动脉粥样硬化患者中等强度他汀联合依折麦布治疗

Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis.
PubMed 文献 · J Am Coll Cardiol · 2023-01-01

该研究为RACING试验的事后分析,纳入3780例动脉粥样硬化性心血管疾病患者,按年龄分层(≥75岁和<75岁)。在≥75岁患者中,中等强度他汀联合依折麦布与高强度他汀单药治疗的主要终点发生率无差异(10.6% vs 12.3%;HR 0.87;95%CI 0.54-1.42;P=0.581),但联合治疗组不耐受相关停药或减量比例更低(2.3% vs 7.2%;P=0.010)。

要点

  • ≥75岁ASCVD患者中,中等强度他汀联合依折麦布与高强度他汀单药的心血管获益相似。
  • 联合治疗显著降低≥75岁患者不耐受相关停药或减量风险(2.3% vs 7.2%)。
  • 高龄患者使用高强度他汀需谨慎,联合方案可作为兼顾疗效与耐受性的选择。

核心结论

  • 在≥75岁ASCVD患者中,中等强度他汀联合依折麦布与高强度他汀单药治疗的心血管获益相似,且不耐受相关停药或减量更少。

研究设计与样本

  • RACING试验的事后分析,共纳入3780例ASCVD患者,按年龄分层为≥75岁(574例,15.2%)和<75岁。

主要发现

  • ≥75岁患者中,联合治疗组与单药组主要终点发生率分别为10.6%和12.3%(HR 0.87;95%CI 0.54-1.42;P=0.581)。
  • <75岁患者中,两组主要终点发生率分别为8.8%和9.4%(HR 0.94;95%CI 0.74-1.18;P=0.570),年龄交互作用P=0.797。
  • ≥75岁患者中,联合治疗组不耐受相关停药或减量比例为2.3%,单药组为7.2%(P=0.010)。
  • <75岁患者中,联合治疗组不耐受相关停药或减量比例为5.2%,单药组为8.4%(P<0.001),年龄交互作用P=0.159。

临床怎么用

  • 对于≥75岁且存在高强度他汀不耐受风险的ASCVD患者,可考虑中等强度他汀联合依折麦布作为替代方案。

局限性

  • 本研究为RACING试验的事后分析,结果需在前瞻性随机对照研究中进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The routine use of high-intensity statins should be considered carefully in elderly patients because of their higher risk of intolerance or adverse events. OBJECTIVES: We evaluated the impact of moderate-intensity statin with ezetimibe combination therapy compared with high-intensity statin monotherapy in elderly patients with atherosclerotic cardiovascular disease (ASCVD). METHODS: In this post hoc analysis of the RACING (RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases) trial, patients were stratified by age (≥75 years and <75 years). The primary endpoint was a 3-year composite of cardiovascular death, major cardiovascular events, or nonfatal stroke. RESULTS: Among the 3,780 enrolled patients, 574 (15.2%) were aged ≥75 years. The rates of the primary endpoint were not different between the moderate-intensity statin with ezetimibe combination therapy group and the high-intensity statin monotherapy group among patients aged ≥75 years (10.6% vs 12.3%; HR: 0.87; 95% CI: 0.54-1.42; P = 0.581) and those <75 years (8.8% vs 9.4%; HR: 0.94; 95% CI: 0.74-1.18; P = 0.570) (P for interaction = 0.797). Moderate-intensity statin with ezetimibe combination therapy was associated with lower rates of intolerance-related drug discontinuation or dose reduction among patients aged ≥75 years (2.3% vs 7.2%; P = 0.010) and those <75 years (5.2% vs 8.4%; P < 0.001) (P for interaction = 0.159). CONCLUSIONS: Moderate-intensity statin with ezetimibe combination therapy showed similar cardiovascular benefits to those of high-intensity statin monotherapy with lower intolerance-related drug discontinuation or dose reduction in elderly patients with ASCVD having a higher risk of intolerance, nonadherence, and discontinuation with high-intensity statin therapy. (RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases [RACING Trial]; NCT03044665).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lee SH, Lee YJ, Heo JH, et al. Combination Moderate-Intensity Statin and Ezetimibe Therapy for Elderly Patients With Atherosclerosis. J Am Coll Cardiol. 2023. PMID: 37019580. doi:10.1016/j.jacc.2023.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。